These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 27502119)

  • 1. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.
    Ziemssen T; Kern R; Cornelissen C
    BMC Neurol; 2016 Aug; 16():129. PubMed ID: 27502119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.
    Ziemssen T; Kern R; Cornelissen C
    BMC Neurol; 2015 Jun; 15():93. PubMed ID: 26084334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
    J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
    Filippi M; Pagani E; Turrini R; Bartezaghi M; Brescia Morra V; Borriello G; Torri Clerici V; Mirabella M; Pasquali L; Patti F; Totaro R; Gallo P; Rocca MA;
    J Neurol; 2024 Sep; 271(9):6181-6196. PubMed ID: 39073436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
    Ziemssen T; Lang M; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Lang S; Winkelmann VE; Ettle B; Schulze-Topphoff U;
    J Neurol; 2022 Jun; 269(6):3276-3285. PubMed ID: 34982201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
    Braune S; Lang M; Bergmann A;
    J Neurol; 2016 Feb; 263(2):327-333. PubMed ID: 26645389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
    Fernández Ó
    Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
    Derfuss T; Bergvall NK; Sfikas N; Tomic DL
    Curr Med Res Opin; 2015; 31(9):1687-91. PubMed ID: 26121423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
    Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
    Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
    Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
    BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.
    Ziemssen T; Lang M; Tackenberg B; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Medin J; Cornelissen C;
    Neurotherapeutics; 2018 Jan; 15(1):190-199. PubMed ID: 29274026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis.
    Walczak A; Kurkowska-Jastrzebska I; Zakrzewska-Pniewska B; Dorobek M; Brola W; Zajdel R; Bartosik-Psujek H; Stasiolek M; Kulakowska A; Rusek S; Tutaj A; Glabinski A; Wlodek A; Kochanowski J; Ciach A; Siger M; Kurowska K; Wicha W; Nojszewska M; Podlecka-Pietowska A; Czajka A; Kapica-Topczewska K; Bielecki B; Maciagowska-Terela M; Stepien A
    Clin Neurol Neurosurg; 2019 Sep; 184():105453. PubMed ID: 31376776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Al Malik Y; Meftah I
    Clin Neuropharmacol; 2020; 43(2):35-38. PubMed ID: 32106137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
    Preziosa P; Rocca MA; Riccitelli GC; Moiola L; Storelli L; Rodegher M; Comi G; Signori A; Falini A; Filippi M
    Neurotherapeutics; 2020 Jan; 17(1):208-217. PubMed ID: 31452082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
    Klotz L; Grützke B; Eveslage M; Deppe M; Gross CC; Kirstein L; Posevitz-Fejfar A; Schneider-Hohendorf T; Schwab N; Meuth SG; Wiendl H
    BMC Neurol; 2015 Jun; 15():96. PubMed ID: 26099927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.